Diseases or Conditions to be Reported

 

DEPARTMENT OF HEALTH

Division of Disease Control

RULE NO.:RULE TITLE:

64DER20-26Diseases or Conditions to be Reported

SPECIFIC REASONS FOR FINDING AN IMMEDIATE DANGER TO THE PUBLIC, HEALTH, SAFETY OR WELFARE: Novel Coronavirus Disease 2019 (COVID-19) is a severe acute respiratory illness that can spread among humans through respiratory transmission and presents with symptoms similar to those of influenza. COVID-19 is a communicable disease with significant morbidity and mortality and presents a severe danger to public health. The World Health Organization has declared COVID-19 as a Public Health Emergency of International Concern. On March 1, 2020, a Public Health Emergency was declared by the Surgeon General to exist statewide in accordance with Executive Order 20-51. On March 9, 2020, Governor Ron DeSantis issued Executive Order 20-52 declaring that a state of emergency exists in the State of Florida. Therefore, there is an immediate need to adopt rules setting forth the procedures to control the spread of COVID-19 to protect the health, safety and welfare of Florida’s citizens.

REASONS FOR CONCLUDING THAT THE PROCEDURE USED IS FAIR UNDER THE CIRCUMSTANCES: COVID-19 presents a public health threat to the state of Florida. The Surgeon General has declared a statewide Public Health Emergency due to the spread of COVID-19. There is an immediate need to set forth procedures for the control of this communicable disease in the State of Florida.

SUMMARY OF THE RULE:  Emergency rule 64DER20-26 (64D-3.029) requires immediate reporting of suspected or confirmed cases and both positive and negative test results of Coronavirus (COVID-19) by physicians, hospitals, and laboratories.

THE PERSON TO BE CONTACTED REGARDING THE EMERGENCY RULE IS: Carina Blackmore, Florida Department of Health, 4052 Bald Cypress Way, Tallahassee, Florida 32399-1703, [phone].

 

THE FULL TEXT OF THE EMERGENCY RULE IS:

 

64DER20-26 (64D-3.029) Diseases or Conditions to be Reported.

(1) through (2) No change

(3) “Table of Reportable Diseases or Conditions to Be Reported”

Practitioner Reporting					Laboratory Reporting
Reportable Diseases or Conditions	Timeframes				Evidence of current or recent infection with etiological agents and all associated testing results performed should be reported (e.g. species, serogroup, serotype, and antimicrobial susceptibility *2 results)	Timeframes
	Suspect Immediately	Immediately	Next Business Day	Other		Submit isolates or specimens for confirmation *1	Suspect Immediately	Immediately	Next Business Day	Other
Any case, cluster of cases, outbreak, or exposure to an infectious or non-infectious disease, condition, or agent found in the general community or any defined setting such as a hospital, school or other institution, not listed in this rule that is of urgent public health significance. This includes human cases, clusters, or outbreaks spread person-to-person, by animals or vectors or from an environmental, food or waterborne source of exposure; those that result from a deliberate act of terrorism; and unexplained deaths possibly due to unidentified infectious or chemical causes.	X	X			Detection in one or more specimens of etiological agents of a disease or condition not listed in this Rule that is of urgent public health significance. This includes the identification of etiological agents that are suspected to be the cause of clusters, or outbreaks spread person-to-person, by animals or vectors or from an environmental, food, or waterborne source of exposure; those that result from a deliberate act of terrorism; and unexplained deaths due to unidentified infectious or chemical causes.		X	X
Acquired Immune Deficiency Syndrome (AIDS)				2 weeks	Acquired Immune Deficiency Syndrome (AIDS)	Laboratory Reporting Not Applicable
Amebic Encephalitis		X			Naegleria fowleri, Balamuthia mandrillaris, or Acanthamoeba species			X
Anthrax	X	X			Bacillus anthracis	X	X	X
Antimicrobial resistance surveillance	Practitioner Reporting Not Applicable				Antimicrobial resistance surveillance (for organisms not otherwise listed in this table), Acinetobacter baumannii, Citrobacter species, Enterococcus species, Enterobacter species, Escherichia coli species, Klebsiella species, Pseudomonas aeruginosa, Serratia species, isolated from a normally sterile site *3				X
Arsenic Poisoning *4a			X		Laboratory results as specified in the surveillance case definition *4a				X
Arboviral infections, not otherwise listed in this table (disease due to) *5	X				Including but not limited to: Flaviviridae, Togaviridae (e.g. chikungunya, Western equine encephalitis), Bunyaviridae (e.g. Heartland, Rift Valley Fever) *5	X	X
Babesiosis			X		Babesia spp.	X			X
Botulism, foodborne, other (includes wound and unspecified)	X	X			Clostridium botulinum or botulinum toxin	X	X	X
Botulism, infant			X		Clostridium botulinum or botulinum toxin	X			X
Brucellosis	X	X			Brucella species	X	X	X
California serogroup viruses (disease due to)			X		California serogroup viruses such as Jamestown Canyon, Keystone, and Lacrosse	X			X
Campylobacteriosis *4b			X		Campylobacter species *4b				X
Cancer (except non-melanoma skin cancer, and including benign and borderline intracranial and CNS tumors) *6				6 months	Pathological or tissue diagnosis of cancer (except non-melanoma skin cancer and including benign and borderline intracranial and CNS tumors)					6 months
Carbon monoxide poisoning			X		A volume fraction ≥ 0.09 (9%) of carboxyhemoglobin in blood				X
CD-4 absolute count and percentage of total lymphocytes	Practitioner Reporting Not Applicable				CD-4 absolute count and percentage of total lymphocytes *7					3 days
Chancroid			X		Haemophilus ducreyi				X
Chlamydia *8			X		Chlamydia trachomatis				X
Cholera	X	X			Vibrio cholerae	X	X	X
Ciguatera fish poisoning			X		Ciguatera fish poisoning	Laboratory Reporting Not Applicable
Congenital anomalies *9				6 months	Congenital anomalies	Laboratory tests as specified in Rule 64D-3.035, F.A.C.
Conjunctivitis in neonates < 14 days old			X		Conjunctivitis in neonates < 14 days old	Laboratory Reporting Not Applicable
Coronavirus (COVID-19) *23		X			Coronavirus (COVID-19) *23			X
Creutzfeld-Jakob disease (CJD) *10			X		14-3-3 or tau protein detection in CSF or immunohistochemical test or any brain pathology suggestive of CJD *10				X
Cryptosporidiosis *4b			X		Cryptosporidium species *4b				X
Cyclosporiasis			X		Cyclospora cayetanensis	X			X
Dengue *5	X				Dengue virus *5	X	X
Diphtheria	X	X			Corynebacterium diphtheriae	X	X	X
Eastern equine encephalitis			X		Eastern equine encephalitis virus	X			X
Ehrlichiosis/Anaplasmosis			X		Anaplasma species or Ehrlichia species	X			X
Escherichia coli Shiga toxin-producing (disease due to) *4b			X		Escherichia coli Shiga toxin-producing *4b	X			X
Giardiasis (acute) *4b			X		Giardia species *4b				X
Glanders	X	X			Burkholderia mallei	X	X	X
Gonorrhea *8			X		Neisseria gonorrhoeae				X
Granuloma inguinale			X		Calymmatobacterium granulomatis				X
Haemophilus influenzae, meningitis and invasive disease, in children < 5 years old	X	X			Haemophilus influenzae, all ages, isolated from a normally sterile site *11	X	X	X
Hansen disease (Leprosy)			X		Mycobacterium leprae				X
Hantavirus infection		X			Hantavirus	X		X
Hemolytic uremic syndrome		X			Not Applicable
Hepatitis A *4b, 12		X			Hepatitis A*4b, 12			X
Hepatitis B, C, D, E and G *12			X		Hepatitis B, C, D, E and G Virus *12				X
Hepatitis B surface antigen (HBsAg)-positive in a pregnant woman or a child up to 24 months old			X		Hepatitis B surface antigen (HBsAg)				X
Herpes B virus, possible exposure		X			Herpes B virus, possible exposure	Laboratory Reporting Not Applicable
Herpes simplex virus (HSV) in infants up to 60 days old with disseminated infection with involvement of liver, encephalitis and infections limited to skin, eyes and mouth *13			X		HSV 1 or HSV 2 by direct FA, PCR, DNA or Culture *13				X
HSV – anogenital in children < 12 years of age *8, 13			X		HSV 1 or HSV 2 by direct FA, PCR, DNA or Culture *13				X
Human immunodeficiency virus (HIV) infection				2 weeks	Repeatedly reactive enzyme immunoassay, followed by a positive confirmatory tests, (e.g. Western Blot, IFA): Positive result on any HIV virologic test (e.g. p24 AG, Nucleic Acid Test (NAT/NAAT) or viral culture). All viral load (detectable and undetectable) test results.*14, 15					3 days
Human immunodeficiency virus (HIV) Exposed Newborn – infant < 18 months of age born to a HIV infected woman			X		All HIV test results (e.g., positive or negative immunoassay, positive or negative virologic tests) for those < 18 months of age					3 days
Human papillomavirus (HPV) associated laryngeal papillomas or recurrent respiratory papillomatosis in children < 6 years of age *8			X		HPV DNA				X
Human papillomavirus (HPV) – anogenital papillomas in children < 12 years of age *8			X		HPV DNA				X
Human papillomavirus (HPV)	Practitioner Reporting Not Applicable				HPV DNA *3				X
Influenza due to novel or pandemic strains	X	X			Isolation of influenza virus from humans of a novel or pandemic strain	X	X	X
Influenza-associated pediatric mortality in persons aged < 18 years		X			Influenza virus – associated pediatric mortality in persons aged < 18 years (if known)	X		X
Influenza	Practitioner Reporting Not Applicable				Influenza virus, all test results (positive and negative) *3				X
Lead poisoning *4, 16			X		All blood lead test results (positive and negative) *3, 4, 16				X
Legionellosis			X		Legionella species				X
Leptospirosis			X		Leptospira species				X
Listeriosis		X			Listeria monocytogenes	X		X
Lyme disease			X		Borrelia burgdorferi				X
Lymphogranuloma Venereum (LGV)			X		Chlamydia trachomatis				X
Malaria			X		Plasmodium species	X			X
Measles (Rubeola)	X	X			Measles virus *16	X	X	X
Melioidosis	X	X			Burkholderia pseudomallei	X	X	X
Meningitis, bacterial or mycotic			X		Isolation or demonstration of any bacterial or fungal species in cerebrospinal fluid				X
Meningococcal disease	X	X			Neisseria meningitidis	X		X
Mercury poisoning *4a			X		Laboratory results as specified in the surveillance case definition *4a				X
Mumps			X		Mumps virus				X
Neonatal Abstinence Syndrome *18				6 months	Neonatal Abstinence Syndrome	Laboratory Reporting Not Applicable
Neurotoxic shellfish poisoning		X			Laboratory results as specified in the surveillance case definition *4a			X
Pertussis		X			Bordetella pertussis			X
Pesticide-related illness and injury *4			X		Laboratory results as specified in the surveillance case definition *4				X
Plague	X	X			Yersinia pestis	X	X	X
Poliomyelitis	X	X			Poliovirus	X	X	X
Psittacosis (Ornithosis)			X		Chlamydophila psittaci	X			X
Q Fever			X		Coxiella burnetii	X			X
Rabies, animal or human		X			Rabies virus		X	X
Rabies, possible exposure *19	X	X			Rabies, possible exposure	Laboratory Reporting Not Applicable
Respiratory syncytial virus	Practitioner Reporting Not Applicable				Respiratory syncytial virus, all test results (positive and negative) *3				X
Ricin toxicity	X	X			Ricinine (from Ricinus communis castor beans)	X	X	X
Rocky Mountain spotted fever and other Spotted Fever Rickettsioses			X		Rickettsia rickettsii and other Spotted Fever Rickettsia species	X			X
Rubella, including congenital	X	X			Rubella virus *17	X	X	X
St. Louis encephalitis (SLE)			X		St. Louis encephalitis virus	X			X
Salmonellosis *4b			X		Salmonella species *4b	X			X
Saxitoxin poisoning including Paralytic shellfish poisoning (PSP)			X		Saxitoxin				X
Severe acute respiratory disease syndrome-associated with a Coronavirus infection	X	X			Coronavirus associated with severe acute respiratory disease	X	X	X
Shigellosis *4b			X		Shigella species *4b				X
Smallpox	X	X			Variola virus (orthopox virus)	X	X	X
Staphylococcus aureus isolated from a normally sterile site	Practitioner Reporting Not Applicable				Staphylococcus aureus isolated from a normally sterile site *3				X
Staphylococcus aureus with intermediate or full resistance to vancomycin (VISA,VRSA)		X			Staphylococcus aureus with intermediate or full resistance to vancomycin (VISA, VRSA); Laboratory results as specified in the surveillance case definition *4	X		X
Staphylococcus enterotoxin B		X			Staphylococcus enterotoxin B	X		X
Streptococcus pneumoniae, invasive disease in children < 6 years, drug sensitive and resistant			X		Streptococcus pneumoniae, all ages, isolated from a normally sterile site *20				X
Syphilis			X		Treponema pallidum				X
Syphilis in pregnant women and neonates		X			Treponema pallidum			X
Tetanus			X		Clostridium tetani				X
Trichinellosis (Trichinosis)			X		Trichinella spiralis				X
Tuberculosis (TB) *21			X		Mycobacterium tuberculosis complex *21	X			X
Tularemia	X	X			Francisella tularensis	X	X	X
Typhoid fever and paratyphoid fever *4b		X			Salmonella enterica serotype Typhi and Salmonella enterica serotypes Paratyphi A, Paratyphi B, and Paratyphi C *4b	X		X
Typhus fever (epidemic)	X	X			Rickettsia prowazekii	X	X	X
Vaccinia disease	X	X			Vaccinia virus	X	X	X
Varicella (Chickenpox) *22			X		Varicella virus				X
Varicella mortality			X		Varicella virus				X
Venezuelan equine encephalitis	X	X			Venezuelan equine encephalitis virus	X	X	X
Vibriosis (infections by Vibrio species and closely related organisms, other than Cholera)			X		All non-cholera Vibrio species Photobacterium damselae, (formerly V. damsela); Grimontia hollisae (formerly V. hollisae)	X			X
Viral hemorrhagic fevers	X	X			Ebola, Marburg, Lassa, Machupo Lujo, new world Arena, or Congo-Crimean hemorrhagic fever viruses	X	X	X
West Nile virus (disease due to)			X		West Nile virus	X			X
Yellow fever	X	X			Yellow fever virus	X		X
Zika fever *5	X				Zika fever virus *5	X	X

 

*1 through *22 No change.

*23– Special reporting requirements for COVID-19: Results should be reported and accompanied by any testing conducted (positive and negative results). For laboratories performing electronic laboratory reporting as described in subsection 64D-3.031(5), F.A.C., all test results (positive and negative) are to be submitted, including screening test results (positive and negative).

Rulemaking Authority 381.0011(2), 381.003(2), 381.0031(8), 384.33, 392.53(2), 392.66 FS. Law Implemented 381.0011(3), (4), 381.003(1), 381.0031(2), (4), (5), (6), (8), 383.06, 384.25, 385.202, 392.53 FS. History–New 11-20-06, Amended 11-24-08, 6-4-14, 10-20-16,____.

 

THIS RULE TAKES EFFECT UPON BEING FILED WITH THE DEPARTMENT OF STATE UNLESS A LATER TIME AND DATE IS SPECIFIED IN THE RULE.

EFFECTIVE DATE: April 10, 2020